tbuckley/cabot-search huggingface dataset:
Near-infrared fluorescence imaging with an MET-targeting probe for biopsy site selection in patients with oral potentially malignant disorders
Authors: Jingbo Wang, Xuemin Shen, Qifan Ma, Lin Yang, Xiaoyu Zhou, Luting Wang, Junqi Cui, Chunye Zhang, Guojun Li, Neil Gross, Siyi Li, Ruimin Huang, Changyou Zhan, Zhen Cheng, Kun Wang, Jie Tian, Ying Yuan, Xiaofeng Tao
Journal: Cell Reports Medicine (2025)

Accurate detection of malignant transformation in oral potentially malignant disorders (OPMDs) is crucial for guiding effective treatment and improving patient management. This study evaluates the potential of MET-binding peptide-indocyanine green (cMBP-ICG), a mesenchymal-epithelial transition factor (MET)-targeted near-infrared fluorescence imaging (NIRFI) probe, for biopsy site selection in OPMDs. Preclinical results demonstrate the superior accuracy of NIRFI-assisted biopsy over conventional oral examination (COE)-based biopsy in detecting high-grade dysplasia (HGD) or squamous cell carcinoma (SCC) and reducing missed detection rates. In a clinical trial with 50 patients, NIRFI-assisted biopsy achieves significantly higher diagnostic accuracy compared to COE-based biopsy (91% vs. 72%, p = 0.0005). These findings underscore the importance of NIRFI in enhancing diagnostic precision, supporting early detection and enabling timely and accurate treatment interventions for patients with OPMDs. The clinical trial is registered under the registration number ChiCTR2300074454.
Further Considerations on Corticosteroid Use in Premature Infants—Reply
Authors: Lex W. Doyle, Rheanna M. Mainzer, Jeanie L. Y. Cheong
Journal: JAMA Pediatrics (2025)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast JAMA+ AI Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2025 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Increased healthcare utilisation in the 5 years preceding systemic lupus erythematosus diagnosis: a Danish nationwide cohort study
Authors: Sofie Geday, Anders Prior, Henrik Schou Pedersen, Annette de Thurah, Esben Næser, Anne Troldborg
Journal: Annals of the Rheumatic Diseases (2025)

This study aimed to analyse healthcare utilisation patterns in the 5 years preceding a diagnosis of systemic lupus erythematosus (SLE) in Denmark compared to matched healthy individuals. Understanding these patterns could support earlier diagnosis and reduce diagnostic delay. A nationwide, registry-based cohort study was conducted using data from the Danish national healthcare registries between 2006 and 2021. Healthcare utilisation, including general practitioner (GP) visits, specialist consultations, prescriptions, blood tests, diagnostic imaging, and hospital admissions, was examined. Incidence rate ratios were calculated using negative binomial regression models adjusted for demographic and clinical covariates. We included 2022 individuals diagnosed with SLE and 20,019 matched reference individuals. 83.8% of patients were female, with an average age of 47.1 years. Even at baseline, patients with SLE exhibited significantly higher healthcare utilisation compared to references for all outcomes which continued throughout the 5-year follow-up. Patients with SLE had approximately 12 annual GP contacts until 1.5 year before diagnosis, where the contact rate increased substantially. Reference individuals consistently had about 4 contacts per year. The incidence rate ratio was approximately 3 during the 5 to 1.5 years preceding diagnosis, increasing to 5.20 (95% confidence interval 4.95-5.46) in the last 6 months before diagnosis. Increased healthcare utilisation years before SLE diagnosis suggests that early symptoms are present and prompt medical attention long before formal diagnosis. These findings highlight the potential for earlier identification of SLE, underscoring the need for improved diagnostic strategies to reduce delays and enhance patient outcomes.
Synergistic Effects of Transarterial Chemoembolization and Lenvatinib on HIF-1α Ubiquitination and Prognosis Improvement in Hepatocellular Carcinoma
Authors: Sung Won Chung, Jin Sun Kim, Won-Mook Choi, Jonggi Choi, Danbi Lee, Ju Hyun Shim, Young-Suk Lim, Han Chu Lee, Kang Mo Kim
Journal: Clinical Cancer Research (2025)

Abstract Purpose: A recent trial has shown that adding transarterial chemoembolization (TACE) to lenvatinib therapy results in enhanced therapeutic efficacy in hepatocellular carcinoma (HCC). We aimed to assess the effectiveness of the lenvatinib and TACE combination in a real-world clinical context for managing HCC and to elucidate the molecular pathways involved. Experimental Design: This retrospective analysis included 199 patients diagnosed with HCC and having intrahepatic lesions between 2018 and 2021. The cohort was divided into those who received lenvatinib plus TACE (n=62, combination group) and those who received lenvatinib monotherapy (n=137, monotherapy group). To further explore the underlying mechanisms, Huh-7 cells were exposed to lenvatinib or a vehicle for 48 hours under normoxic or hypoxic condition. Results: Propensity score-matched analysis revealed a significant improvement in both overall survival (adjusted hazard ratio [aHR], 0.38; 95% CI, 0.24–0.59; P&amp;lt;0.001) and progression-free survival (aHR, 0.41; 95% CI, 0.26–0.64; P&amp;lt;0.001) in the combination group compared to the monotherapy group. In laboratory experiments, under hypoxic conditions, lenvatinib notably attenuated hypoxia-inducible factor-1 alpha (HIF-1α) protein levels in Huh-7 cells without altering its mRNA levels. Intriguingly, lenvatinib facilitated the MDM2-mediated ubiquitination and subsequent degradation of HIF-1α. Additionally, cell viability assays confirmed a significant decrease in Huh-7 cell survival following lenvatinib treatment under hypoxic conditions. Conclusions: The combination of lenvatinib and TACE significantly improved survival in HCC patients. The mechanistic foundation appears to be the lenvatinib-triggered degradation of HIF-1α via the MDM2-dependent ubiquitination pathway, highlighting a potential therapeutic target in HCC treatment.
PD-1 or PD-L1—A Difference That Makes No Difference?
Authors: Samuel J. Klempner, Jeeyun Lee, Raghav Sundar
Journal: JAMA (2025)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors JAMA+ AI Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2025 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pembrolizumab with chemotherapy for patients with recurrent or metastatic nasal cavity and paranasal sinus squamous cell carcinoma: A prospective phase ll study
Authors: Yuquan Qian, Le Tang, Jiarui Yao, Yiming Zhu, Ye Zhang, Haizhen Lu, Weihua Li, Changming An, Lin Gui
Journal: Clinical Cancer Research (2025)

Abstract Purpose: Patients with recurrent or metastatic sinonasal squamous cell carcinoma (R/M SNSCC) lack standardized systemic treatment and prospective studies. We evaluated the anti-tumor response and safety of pembrolizumab with nab-paclitaxel and platinum in R/M SNSCC. Patients and Methods: R/M SNSCC patients received pembrolizumab 200mg, nab-paclitaxel 260mg/m2 plus cisplatin 75 mg/m2 or carboplatin at an area under the curve 5 on day 1 every 21 days for up to six cycles, followed by pembrolizumab maintenance until progression or unacceptable toxicity or 35 cycles. The primary endpoint was objective response rate (ORR). Secondary endpoints were disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and safety. Immunohistochemistry and high-resolution sequencing of the tumor samples were performed. Results: The ORR in 20 patients was 60.0% (95% CI: 36.1%-80.9%) and two patients (2/20, 10%) achieved CR. The DCR was 100%. Median follow-up was 18.1 months (range:5.2-31.7), the median PFS was 12.2 months (95% CI: 9.0 months-not estimated) and the median OS was not reached. Patients with PD-L1 CPS ≥20 exhibited better ORR (80.0% vs 28.6%, p=0.144), median PFS (not reached vs 7.0 months, p=0.0137), and median OS (not reached vs 17.8 months, p=0.0401) compared to those with PD-L1 CPS &amp;lt; 20. Grade 3/4 treatment-related adverse events (AE) accounted for 30.0% (6/20), and all come from hematologic toxicity. Hypothyroidism was the most common immune-related AE (12/20, 60.0%). Conclusions: Pembrolizumab plus nab-paclitaxel and platinum shows promising antitumor activity and manageable safety in first-line R/M SNSCC patients.
A Systematic Review with a Demonstrative Case of KIT and DOG-1 Expressing Gastrointestinal Stromal Tumors Harboring ETV6-NTRK3 Fusions
Authors: Tannaz Ranjbarian, Mark Antkowiak, Robert J. Mallory, Terence M. Doherty, Mojgan Hosseini, Jill P. Mesirov, Paul T. Fanta, Jason K. Sicklick
Journal: Clinical Cancer Research (2025)

Abstract Introduction: Previous reports have described ETV6-NTRK3 fusion-positive gastrointestinal stromal tumors (GISTs) in cases lacking KIT, PDGFRA, RAS-pathway, or SDHx alterations. However, some investigators have questioned the rigor of these reports and the true existence of NTRK rearrangements in GIST. This study aims to: 1) resolve whether NTRK gene rearrangements exist in GIST; 2) review the relevant literature; and 3) demonstrate a case of NTRK fusion GIST. Methods: A comprehensive literature review using PubMed identified additional NTRK fusion-reported cases. Under an IRB-approved protocol, we describe a patient with biopsy-proven GIST who underwent genomic and transcriptomic CLIA-certified testing, precision-matched therapy, surgical resection, and pathological analysis. Results: We identified 17 reported cases of GIST with NTRK fusions. Five studies reported GIST with KIT/DOG-1 expression by IHC, wild-type KIT/PDGFRA, and an ETV6-NTRK3 fusion, consistent with GIST. We demonstrate a case of a 72-year-old female status post resection of a high-risk gastric GIST followed by 45 months of adjuvant imatinib. She developed recurrent disease and biopsy revealed mixed epithelioid and spindleoid GIST with IHC expression of KIT (CD117) and DOG-1. Imatinib was re-initiated, but her disease progressed, prompting molecular testing for the first time. RNA sequencing identified an in-frame fusion of ETV6 with NTRK3. Larotrectinib, a pan-NTRK inhibitor, was initiated for 7 months, resulting in shrinkage in five tumors (range: 4.2–77%). Surgical cytoreduction demonstrated a pathological near complete response (1% viable tumor cells). Conclusion: Our findings confirm the existence of ETV6-NTRK3 fusion GIST and demonstrate that these imatinib-resistant GISTs may be exquisitely sensitive to TRK
Efficacy of cognitive behavioral therapy and acceptance- and mindfulness-based treatments in adults with bodily distress – a network-meta-analysis
Authors: Frederic Maas genannt Bermpohl, Alexandra Martin
Journal: Psychotherapy and Psychosomatics (2025)

Introduction: Many physical complaints cause long-term bodily distress. Meta-analyses show that cognitive behavioral therapy (CBT) and acceptance- and mindfulness-based treatments (AMBT) reduce somatic symptom severity, but evidence on differential efficacy is limited. Objective: This study evaluates the efficacy of CBT and AMBT for bodily distress (e.g., somatoform disorders, functional somatic syndromes, and related disorders). Methods: A network meta-analysis of randomized controlled trials on adults with bodily distress compared CBT and AMBT either directly or with non-specific control groups. Cohen’s d based on between-group effect sizes was aggregated using a random effects model. Primary outcome was somatic symptom severity; secondary outcomes included depression, anxiety, and perceived health status. Results: Based on 74 studies (N = 8,277), CBT (d = -0.50, 95%CI -0.70 to -0.29; between-group effect sizes vs. wait-list) and AMBT (d = -0.55, 95%CI -1.06 to -0.23; between-group effect sizes vs. wait-list) were equally effective in reducing somatic symptoms at post-treatment. AMBT were more effective than CBT in reducing depression (d = -0.31, -0.58 to -0.04; between-group effect sizes) and anxiety (d = -0.42, -0.73 to -0.11; between-group effect sizes) post-treatment. At long-term follow-up, effects were partly maintained; AMBT remained more effective than CBT for anxiety, with no differential effects for other outcomes. Conclusions: Both treatments showed benefits compared to various controls. Evidence suggests potential differential treatment effects, indicating some patient groups may benefit more from AMBT. Clinicians should view CBT as foundational but remain open to variations, especially for comorbid pathology.
The Power of Professional Clinical Ethicists in Low- and Middle-Income Countries: An Ethiopian Perspective
Authors: Merhawit Abadi, Redeat Workneh, Stephanie Kukora, Krystle Perez, Gregory Valentine, Gal Barbut, Betelehem B. Kassa, Mahlet Abayneh, Sharla Rent
Journal: The American Journal of Bioethics (2025)
Splicing factor RBM10 loss fuels thyroid cancer metastasis
Authors: Kevin Coughlin, Ledong Wan
Journal: The Journal of Experimental Medicine (2025)

In this issue of JEM, Krishnamoorthy et al. (https://doi.org/10.1084/jem.20241029) identify the loss of the splicing factor RBM10 as a driver of metastasis in thyroid cancer through the regulation of RNA splicing. The synthetic lethal interaction between NF-κB and RBM10 loss reveals a potential therapeutic vulnerability.
99mTc-PSMA Scintigraphy of Subcutaneous Angiolipoma
Authors: Amin Saber Tanha, Zahra Rafiei, Nasrin Raeisi, Naser Tayyebi Meibodi, Atena Aghaee
Journal: Clinical Nuclear Medicine (2025)

We present a case of a 69-year-old man diagnosed with prostate adenocarcinoma, who underwent 99m Tc-PSMA scintigraphy as part of his initial staging workup. The scan revealed a focal uptake in the posterior abdominal wall, corresponding to a subcutaneous soft tissue lesion. Further evaluation using SPECT/CT imaging localized the lesion, which was subsequently excised and histopathologically diagnosed as an angiolipoma. This case represents the first reported instance of PSMA-based detection of angiolipoma as a false-positive finding using 99m Tc-PSMA scintigraphy.
Radiation Exposure to Patients and Others During Therapy for Pediatric Neuroblastoma With Lu-177-DOTATATE
Authors: Zhaoqi Lu, Yanjinghui Sun, Di Zuo, Pengfei Li, Xiaorong Sun
Journal: Clinical Nuclear Medicine (2025)

Purpose: This study evaluated Lutetium-177-(DOTA°,Tyr 3 ) octreotate (Lu-177-DOTATATE) clearance in pediatric patients with neuroblastoma and assessed the effective doses received by patients, family caregivers, and medical staff during therapy. Patients and Methods: Twenty-three children (3–13 y) who received Lu-177-DOTATATE between 2023 and 2024 were enrolled. External dose rates were measured at 0, 1, 2, 4, 6, 24, 48, and 96 hours post-administration to estimate patients’ Lu-177-DOTATATE retention rate, the effective half-life, and the maximum cumulative effective dose around patients. Whole-body and red-marrow absorbed doses were calculated based on multi-time-point whole-body planar and SPECT/CT imaging using HERMES Dosimetry software. Whole-body effective doses to family caregivers and medical personnel were measured using thermoluminescence dosimeters (TLDs), and effective finger doses for medical staff were measured using ring TLDs. Results: The mean administered activity was 3.687±1.545 (range, 1.469–7.368) GBq. Whole-body retention rates at 1–96 hours post-administration ranged from 72.0% to 10.0%, with 99% clearance expected within 11 days. Clearance followed a biexponential decay model, with estimated effective half-lives of 1.4±0.8 and 52.3±18.6 hours for the fast and slow phases, respectively, at 2 m. Estimated maximum cumulative effective doses (within 11 days) at 1 and 2 m were 0.442±0.174 and 0.138±0.058 mSv, respectively. Absorbed doses for children were 0.159±0.076 mGy/MBq (whole body) and 0.611±0.416 mGy/MBq (red-marrow). Whole-body effective doses to family caregivers averaged 0.245±0.063 (range, 0.150–0.390) mSv. The whole-body and finger-effective doses to the radiopharmacists were 3.7±1.8 and 155.3±73.0 μSv/patient, respectively. The mean of whole-body and the median ( P 25 , P 75 ) of finger-effective doses to nurses were 4.7±1.4 μSv/patient and 16.7 (10, 470) μSv/patient, respectively. Conclusion: Lu-177-DOTATATE was rapidly cleared in children with neuroblastoma. Radiation exposure to others was below personal dose limits.
One-Stop 68Ga-FAPI/18F-FDG Total-Body PET/CT Scan
Authors: Huaping Gao, Han Tang, Zhe Zheng, Haojun Yu, Wujian Mao, Yu Lin, Jiefu Zheng, Akram Al-Ibraheem, Yibo He, Wenxin Tang, Runjun Yang, Yunze Xie, Lijie Tan, Hongcheng Shi
Journal: Clinical Nuclear Medicine (2025)

Purpose: This prospective study aims to assess the feasibility of a one-stop imaging protocol using 68 Ga-FAPI-04/ 18 F-FDG dual-radiotracer with dual-low-activity for tumor imaging. Patients and Methods: Forty patients underwent one-stop 68 Ga-FAPI-04 PET (PET FAPI ) and dual-radiotracer PET (PET DUAL ) using a total-body PET/CT scanner with a 194-cm axial field of view. After a half-dose (0.925 MBq/kg) 68 Ga-FAPI-04 PET/CT, an additional half-dose (1.85 MBq/kg) of 18 F-FDG was administered for a 60-minute dynamic acquisition. PET DUAL was reconstructed at 10-minute intervals (PET D0–10 , PET D10–20 , PET D20–30 , PET D30–40 , PET D40–50 , and PET D50–60 ). Data of lesion detectability, target-to-background ratios, tumor staging, and total radiation dose were analyzed. A target-to-liver ratio (TLR) ≥ 3 on PET FAPI was considered indicative of sufficient fibroblast activation protein expression. Results: PET D50–60 and PET FAPI showed similar performance in detecting primary tumors (42 vs 41, P &gt; 0.999). However, significantly more metastatic lesions were identified on PET D50–60 compared with PET FAPI (102 vs 60, P &lt; 0.001). PET FAPI demonstrated significantly higher TLR, target-to-blood-pool ratio, and target-to-normal-tissue ratio than PET DUAL ( P &lt; 0.05). Lesion detectability was similar across PET D10–20 , PET D20–30 , PET D30–40 , PET D40–50 , and PET D50–60 (all P ’s &gt; 0.05). Notably, PET D30–40 and PET D40–50 detected all lesions identified by PET D50–60 . PET D40–50 showed no significant differences in TLR, target-to-blood-pool ratio, and target-to-normal-tissue ratio compared with PET D50–60 ( P &gt; 0.05). Up to 94.9% of malignant primary lesions exhibited a TLR ≥ 3 on PET FAPI . The average effective dose was 9.85 ± 2.19 mSv, similar to that of a whole-body 18 F-FDG PET/CT. Conclusions: This one-stop, dual-radiotracer, dual-low-activity imaging protocol combines the strengths of 68 Ga-FAPI-04 and 18 F-FDG, offering a shorter imaging duration and reduced radiation exposure.
CXCL12 Derived From ACKR1 <sup>+</sup> Intraplaque Neovessels Mediates CD8 <sup>+</sup> T Cell Recruitment in Human Atherosclerosis
Authors: Laura Parma, Nadja Sachs, Nikola Sobczak, Zhaolong Li, Kevin Merchant, Jessica Pauli, Marie A.C. Depuydt, Anouk Wezel, Harm J. Smeets, Ilze Bot, Bram Slütter, Lars Maegdefessel, Christian Weber, Johan Duchêne, Remco T.A. Megens
Journal: Circulation (2025)
Newborn Screening Using Genome Sequencing for Early Actionable Conditions
Authors: Gujie Wu, Lin Cheng, Caiyun Lei
Journal: JAMA (2025)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors JAMA+ AI Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2025 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A model of intra-tumor and inter-patient heterogeneity explains clinical trials of curative combination therapy for lymphoma
Authors: Amy E. Pomeroy, Adam C. Palmer
Journal: Blood Cancer Discovery (2025)

Abstract Models of tumor drug response have illuminated important concepts in oncology, but there remains a need for theory that combines intra-tumor and inter-patient heterogeneity to explain patient outcomes, especially for curative treatments. We present a mathematical model of multi-drug therapy that describes both cell-to-cell and patient-to-patient heterogeneity as distributions of drug sensitivity, and apply it to simulate curative combination therapies for Diffuse Large B-Cell Lymphoma (DLBCL). Simulated trials reproduced Progression-Free Survival and changes in circulating tumor DNA observed under standard therapy, and accurately predicted success or failure of nine randomized trials of first-line combinations based on drugs’ efficacies in relapsed/refractory DLBCL. Finally, we used the model to explore how drug synergies, biomarkers, and subtype-specific endpoints could improve the chance of success of targeted combination therapies. This study offers a quantitative model of curative drug combinations and suggests that predictive simulations could aid the design of new regimens with curative intent.